Eli Lilly (LLY) said Wednesday that its obesity drug Zepbound spurred more weight loss than Novo Nordisk's Wegovy in the first head-to-head clinical trial. Eli Lilly stock edged higher in early trade while Novo Nordisk (NVO) was little changed.
Lilly's Zepbound reduced patients' weight by 20.2% after 72 weeks, or about 50 pounds. That's vs. 13.7%, or roughly 33 pounds, for Novo Nordisk drug Wegovy.
↑ XAlso, nearly 32% of Zepbound patients lost at least a one-fourth of their body weight vs. 16% for Wegovy takers.
The Eli Lilly-spurred study results are not a shock, given that separate studies have signaled that its Zepbound bests Novo's Wegovy on weight loss.
Zepbound's active ingredient is tirzepatide, a dual GIP and GLP-1 receptor agonist. Wegovy's semaglutide is a GLP-1 receptor agonist.
In premarket trade, Eli Lilly stock rose 0.7%. Novo Nordisk stock was essentially flat.
YOU MAY ALSO LIKE:
Why This IBD Tool Simplifies The Search For Top Stocks
Catch The Next Big Winning Stock With MarketSurge
Best Growth Stocks To Buy And Watch
IBD Digital: Unlock IBD's Premium Stock Lists, Tools And Analysis Today
Futures Rise On Earnings; 3 Hot AI Stocks
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。